AIM ImmunoTech CEO and President Thomas K. Equels reports acquisition of $5,093.75 in common shares
AIM•AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 31,250 common shares at $0.163 each, increasing his direct beneficial ownership to 158,072 shares.
1. Share purchase
Equels purchased 31,250 shares of common stock at $0.163 each, increasing his direct beneficial ownership to 158,072 shares.
